Loading clinical trials...
Loading clinical trials...
Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom (Fixed Combination Of Latanoprost And Timolol) In Patients With Poag Or Oh. A 6-Month, Open, Multi-Center Trial In Italy
This study is designed as an open label evaluation of the efficacy of latanoprost and timolol fixed combination (Xalacom) after 6 month of treatment. Eligible patients may be enrolled at the baseline visit. All current ocular hypotensive therapy must be discontinued at this time. On baseline day, patients eligible for the study will receive Xalacom which is to be instilled in the morning.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Pfizer Investigational Site
Arezzo, Italy
Pfizer Investigational Site
Bari, Italy
Pfizer Investigational Site
Bollate, Italy
Pfizer Investigational Site
Bologna, Italy
Pfizer Investigational Site
Caserta, Italy
Pfizer Investigational Site
Catanzaro, Italy
Pfizer Investigational Site
Conegliano, Italy
Pfizer Investigational Site
Desenzano (BS), Italy
Pfizer Investigational Site
Ferrara, Italy
Pfizer Investigational Site
Livorno, Italy
Start Date
May 1, 2003
Completion Date
April 1, 2006
Last Updated
February 21, 2021
250
Estimated participants
Xalacom
DRUG
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07396441